p20: progesterone in tbi treatment

Authors

elham mohammadzadeh a. shefa neuroscience research, khatam alanbia hospital, tehran, iran b. department of biology and anatomical sciences, faculty of medicine, shahid beheshti university of medical sciences,tehran, iran

abstract

the brain edema is one of remarkable injuries after traumatic brain injuries (tbi). the common treatments for limiting edema are included mannitol, barbiturates, corticosteroids, hyperventilation and central nervous system derange. the most of these treatments for edema is problematic. for example, mannitol can be effective for the short period of time (24 hours) after brain injuries but is not appropriate for long-term treatments after tbi. also, the application of corticosteroids such as methylprednisolone was encountered with limited treatments. on the other hand, the studies were shown that biological gender effects incidence and the result of ischemia and tbi and gender and menstruation may have an effect on animal response to experimental tbi and finally lead to progesterone development as a neuroprotective factors. progesterone is synthesized in males and females’ brain by oligodendrocytes and some neurons in equally volume. progesterone receptors are expressed in adult brain, thus the various regions of brain are natural target of progesterone. the investigations on progesterone were shown that this hormone has been used as a treatment after injury due to stroke and tbi in males and females. moreover, animal studies were shown that the use of progesterone after experimental tbi decreases neuronal apoptosis and limit gliosis. progesterone injection leads to decrease neuronal death, increase remyelination and improve function and overall decrease in brain edema.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

P20: Progesterone in TBI Treatment

لطفاً به چکیده انگلیسی مراجعه شود.

full text

Embracing failure: What the Phase III progesterone studies can teach about TBI clinical trials

BACKGROUND Despite positive preclinical studies and two positive Phase II clinical trials, two large Phase III clinical trials of progesterone treatment of acute traumatic brain injury (TBI) recently ended with negative results, so a 100% failure rate continues to plague the field of TBI trials. METHODS This paper reviews and analyses the trial structures and outcomes and discusses the implic...

full text

Traumatic Brain Injury (TBI): Overview of Diagnosis and Treatment

Traumatic brain injury (TBI) is a common, preventable, and disabling health condition with heterogeneous aetiology, type, severity, and outcomes. Ongoing challenges in TBI care are reflected by rapidly growing literature in the prevention, assessment and treatment of TBI, especially in sports concussion and blast-related TBI. Recent advances include TBI modelling, to predict outcomes of TBI and...

full text

Effect of Post-Mating GnRH Treatment onSerum Progesterone Profile and Conception Rate in Buffaloes

The present study was designed to investigate the impact of exogenous administration of GnRH (Receptal VET®, Intervet Pharmaceuticals Ltd., India) on serum progesterone profile and conception rates during mid luteal phase of estrous cycle in buffaloes. Estrus was induced using Cyclix 2 mL. i/m. (Intervet India Pvt. Ltd., India) and animals were bred naturally during observed estrus. The buffalo...

full text

P 112: Combining Granulocyte-Colony Stimulating Factor (G-CSF) and Stem Cells in Treatment of Traumatic Brain Injury (TBI)

Traumatic brain injury (TBI) is described as a situation in which the brain is damaged by an external force. It is considered to be a chief problem in health care. Pharmacotherapy and stem cell therapy are the main treatments used in TBI. The purpose of these procedures is to control the inflammation in injured regions of brain. Currently, there is no effective care for TBI that could regenerat...

full text

My Resources

Save resource for easier access later


Journal title:
مجله علوم اعصاب شفای خاتم

جلد ۳، شماره ۴، صفحات ۴۷-۴۷

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023